Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer

Table 10 ORs for the development of gastric non-cardia cancer with IL-8-251, +396 and +781 polymorphisms

	Genotype	NUD (n)	Cancer (n)	OR	95% CI	P value	Ulcer (n)	OR	95% CI	P value
IL-8-251	T/T	2000	978	-			370
	T/A	2518	1244	1.01	0.91-1.12	0.38	532	1.14	0.99-1.32	0.07
	A/A	892	401	0.92	0.80-1.06	0.24	163	0.99	0.81-1.21	0.90
	A carrier	3410	1645	0.99	0.90-1.09	0.18	695	1.10	0.96-1.26	0.17
IL-8+396	T/T	224	27	-
	T/G	293	43	1.22	0.73-2.03	0.44
	G/G	93	12	1.07	0.52-2.20	0.85
	G carrier	385	55	1.18	0.73-1.93	0.50
IL-8+781	C/C	248	29	-
	C/T	282	41	1.24	0.75-2.06	0.39
	T/T	84	11	1.12	0.54-2.34	0.76
	T carrier	366	52	1.22	0.75-1.97	0.43

NUD includes patients with gastritis without gastric cancer and peptic ulcer, and atrophic gastritis. Because we deleted a number of gastric cardia cancer patients, the number of cancer patients shown in this Table does not match that in Table 4.